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ABSTRACT
Malaria remains a significant public health challenge and is of global importance. Imported
malaria is a growing problem in non-endemic areas throughout the world and also in Qatar
due to a massive influx of migrants from endemic countries. Antimalarial drug resistance is an
important deterrent in our fight against malaria today. Molecular markers mirror intrinsic
antimalarial drug resistance and their changes precede clinical resistance. Thus, in the present
study, molecular markers of sulphadoxine-pyrimethamine (Pfdhfr and Pfdhps) and artemisinin
(PfATPase6 and Pfk13) were sequenced to determine the drug resistance genotypes among
118 imported P. falciparum isolates in Qatar, between 2013 and 2016. All the isolates had
mutant Pfdhfr alleles, with either double mutant (51I/108N) (59.3%) or triple mutant (51I, 59R
and 108N) (30.6%) genotypes. I164L substitution was not found in this study. In case of
Pfdhps, majority of the samples were carriers of either single (S436A/ A437G/ K540E) mutant
(47.2%) or double (S436A/K540E, A437G/K540E, K540E/A581G) mutant (39.8%). A single novel
point mutation (431V) was observed in the samples originated from Nigeria and Ghana.
Polymorphisms in PfATPase6 were absent and only one non-synonymous mutation in Pfk13
was found at codon G453A from a sample of Kenyan origin. High levels of sulphadoxine-
pyrimethamine resistance in the present study provide potential information about the
spread of antimalarial drug resistance and will be beneficial for the treatment of imported
malaria cases in Qatar.
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Introduction
More than a century ago after its discovery, and more
than six decades of efforts to control it, malaria
remains a serious health problem in most tropical
and subtropical countries. The World Health
Organization (WHO) estimates that 3.3 billion people
are at risk of malaria infection, 219 million clinical
cases and 435,000 deaths globally in 2017 [1]. Qatar
has been free from local malaria transmission since
1970 [2], however, an influx of migrant workers from
malaria-endemic countries, representing a major
threat for re-introduction of local drug resistance
malaria transmission [3–6]. In addition to the flow of
imported cases, the receptivity and risk of malaria
reintroduction are evident by the presence of the
mosquito vectors, Anopheles stephensi and An.
multicolor [4,7,8]. This situation is similar to that in
other countries of the Arabic Peninsula [9]. Currently,
according to the national guidelines, artemisinin-
based combination therapies (ACT) and artesunate/
doxycycline or quinine/clindamycin is recommended
for uncomplicated and complicated/severe
P. falciparum malaria, respectively. However, chloro-
quine (CQ) followed by primaquine is the first-line
regimen for the treatment of P. vivax malaria in
Qatar. Moreover, mixed infections are usually treated
as P. falciparum malaria.
Resistance to the antifolate sulphadoxine-
pyrimethamine (SP) has been found to be associated
with key point mutations in the dihydrofolate reduc-
tase (dhfr) and dihydropteroate synthase (dhps) genes.
The level of resistance to SP has been shown to
CONTACT Devendra Bansal dbansal@moph.gov.qa; als2026@qatar-med.cornell.edu Department of Microbiology and Immunology, Weill
Cornell Medicine - Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar
*Present address: Ministry of Public Health, Qatar
Supplemental data for this article can be accessed here.
PATHOGENS AND GLOBAL HEALTH
2019, VOL. 113, NO. 4, 158–166
https://doi.org/10.1080/20477724.2019.1639018
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered,
transformed, or built upon in any way.
increase with the accumulation of mutations at
codons 16, 51, 59, 108 and 164 as the Pfdhfr inhibit
its activity, and the parasite becomes resistant to
pyrimethamine. While mutations at codons 436, 437,
540, 580 and 613 of Pfdhps reduce the substrate
binding capacity and confer resistance to sulphadox-
ine [10,11].
The exact mechanism of action of ACTs is still
a matter of debate but, recent emergence of
P. falciparum artemisinin (ART) resistance in southeast
Asia threatens the global efforts to control malaria.
Hitherto, several studies provide compelling evidence
that ACTs act by selectively inhibiting sarcoplasmic/
endoplasmic reticulum Ca++-ATPase ortholog in
P. falciparum (PfATPase6) protein, believed to be the
primary target (at codon S769N) for ART, but is not yet
fully confirmed [12–15]. In recent years, mutations in
the propeller region of a kelch protein (K13) were
associated with ART-resistant isolates [16,17], which
was further confirmed by in vitro and ex vivo stu-
dies [18].
Monitoring drug resistance and pattern of muta-
tions is essential for early detection and subsequent
preventions of the spread of drug resistance. Hence,
there is a need for monitoring antimalarial drug resis-
tance in Qatar for prompt management of imported
P. falciparum malaria, as majority of immigrant work-
ers come from malaria-endemic countries, namely
India, Pakistan and Sudan [3,4,6]. Therefore, the pre-
sent study was conducted to determine the preva-
lence of point mutations involved in antimalarial
resistance genes Pfdhfr, Pfdhps (SP) and PfATPase6,
K13 (ART) among imported P. falciparum isolates in
Qatar. The study’s findings will generate a new under-
standing of the disease as well as baseline information
on antimalarial drug resistance among imported
P. falciparum in Qatar.
Materials and methods
Study area, sample collection and ethical
approval
The present study was carried out in Doha, Qatar,
during January 2013–September 2016. Details of the
study’s population characteristics have previously
been described [19]. The venous blood samples from
583 symptomatic patients attending the Hamad
General Hospital (HMC), Doha, Qatar were collected
in sterile vacutainer and screened for malaria parasites
by microscopy, and species identification was con-
firmed by species-specific nested PCR [20]. Socio-
demographics information including age, gender,
nationality, treatment and clinica was collated using
a structured questionnaire and from patient’s medical
records. The ethical clearance for patient’s partici-
pants and sample collections was obtained from
Hamad Medical Corporation and Weill Cornell
Medicine-Qatar Institutional Review Board (Protocol
no. – 14–00097).
DNA extraction, nested PCR and sanger
sequencing
The genomic DNA of P. falciparum was extracted
using QIAamp DNA blood mini kit as per the manu-
facturer’s instructions (Qiagen, CA, USA).
Alleles of the Pfdhfr, Pfdhps genes (for SP resis-
tance) and K-13 propeller, PfATPase6 (for ART resis-
tance) were determined using nested PCR followed
by sanger sequencing, as previously described pro-
tocols with some minor modifications [21]. Primers
for primary and nested PCR, and PCR cycling condi-
tions are listed in the supplementary material [21].
The spanning codons 51–164 of Pfdhfr gene, codons
425–640 of Pfdhps gene codons 653–797 of
PfATPase6 and codon 427–702 of K-13 propeller
were amplified by PCR. In brief, primary PCR was
performed with 2 μL extracted genomic DNA (5ng/
μL), 12.5 μl of 2X Master mix (Applied Biosystems,
CA, USA), 1μM each primer and the mixture was
made up to 25 μL volume with nuclease-free
water (Ambion, CA, USA). The PCR products were
purified using MinElute PCR Purification Kit accord-
ing to the manufacturer’s instructions (Qiagen, CA,
USA). Purified products were sequenced using the
Sanger method (Genewiz INC, NJ, USA) with
respected-nested primers. Obtained DNA sequences
were edited manually in BioEdit9 and aligned using
ClustalW10. Multiple Sequence Alignment (MSA)
was performed to see intraspecific variation if any,
among the sequences. The presence or absence of
mutations was assessed by comparing each
sequence to the P. falciparum 3D7 reference strain
for dhps (PF3D7_0810800), dhfr (PF3D7_0417200),
ATPase6 (PF3D7_0106300) andk13
(PF3D7_1343700). In order to determine the associa-
tion between SNPs (present in Pfdhfr and Pfdhps) in
the population, both inter and intragenic linkage
disequilibrium (LD) tests were performed using the
Haploview Software [22].
Statistical analysis
Statistical analyses were performed using IBM SPSS
version 22.0 (Armonk, NY: IBM Corp). Frequencies of
alleles and genotypes among parasite groups were
compared using the X [2] test. The P values <0.05
were considered statistically significant. Unadjusted
odds ratios (ORs) of mutant alleles among different
parasite origins along with their 95% confidence inter-
vals (CI) were calculated using Univariate logistic
regression model.
PATHOGENS AND GLOBAL HEALTH 159
Results
A total of 583 patients were examined by microscopy
followed by PCR for malaria between January 2013
and October 2016 in Hamad General Hospital and Al-
Khor Hospital, 448 (76.8%) were found to be positive
for malaria parasites. The majority were infected with
P. vivax (n = 318 [71%]), followed by P. falciparum (n =
118 [26.3%]) and mixed P. falciparum and P. vivax (n =
12 [2.7%]) were less frequent.
The majority of malaria patients were male, with
a mean age of 33 years (95% CI 30.0–35.0). The vast
majority of P. falciparum cases originated from East
Africa (60%, n = 71) followed by the Indian subcontinent
(20.3%, n = 24), West and Central Africa (17.8%, n = 21)
and less frequently from Oman or Yemen and Saudi
Arabia (1.7%, n = 2) (Figure 1). The origin of the majority
of patients of P. vivax was from the Indian-subcontinent
(81.8%) followed by East Africa (10.7%) and different parts
in Africa (6%).
Prevalence of pfdhfr alleles and genotypes
Out of 118 P. falciparum isolates, 108 (91.5%) were suc-
cessfully amplified, sequenced and analyzed for Pfdhfr
gene. All the isolates were mutant either single, double,
triple and/or quadruple. Most of the sequenced isolates
showed amutation at codons N51I (89.8%), C59R (36.1%)
and S108N (94.4%). However, no mutation was seen at
codon I164L (Table 1). In addition, four novel mutations
were detected at codons 185, 178, 183 and 181.
Out of 108 samples genotyped, a large proportion
(59.3%) of the isolates carried the double mutants geno-
type, while the triple mutant genotypes were detected in
30.6% isolates. However, the prevalence of quadruple
mutant genotypes was only 1.9% (Figure 2). The fre-
quency of triple mutation was high in West and Central
Africa, andquadruplemutationwas foundonly in the East
Africa isolates (Figure 2)
Based on the geographical location, eight genotypes
were detected (ACICSILYT, ACNCNILYT, ACICNILYT,
ACNRNILYT, ACIRNILYT, ACICNISYT, ACIRNILYA and
ACIRNILHT) in 67 East Africa isolates. A majority of the
samples (65.7%) harbored thedoublemutants ACICNILYT
followed by triple mutants ACIRNILYT (20.9%) and single
mutant ACICSILYT (4.5%) genotype. While among the
isolates from the Indian subcontinents, seven different
genotypes (ACNCSILYT, ACICSILYT, ACNCNILYT,
ACNRNILYT, ACICNILYT, ACNCNILHT and ACIRNILYT)
were found. Of these, 30%, 25% and 5% harbored double
mutant genotypes (ACNRNILYT, ACICNILYT and
ACNCNILHT), respectively. The triple mutant genotype
ACIRNILYT were detected in 20%. The single mutant
genotypes (ACNCNILYT, ACICSILYT and ACNCSILYT)
were carried by 10%, 5% and 5% isolates, respectively.
However, in West and Central Africa, we observed only
four genotypes (ACICSILYT, ACICNILYT, ACIRNILYT and
ACICNILHT) and most of the isolates (62%) carried triple
mutant (ACIRNILYT) followed by double mutant
(ACICNILYT) (28.6%) genotypes (Table 2). Further analysis
revealed that triple mutants were significantly higher in
Figure 1. A map showing the countries of origin of the patients from whom Plasmodium falciparum samples were collected in
Doha, Qatar.
Table 1. Frequency (%) and number (n) of the Pfdhfr and
Pfdhps mutations.
Mutant alleles n = 108 (%)
Pfdhfr
51I 97 (89.8)
59R 39 (36.1)
108N 102 (94.4)
178S 1 (0.9)
181N 1 (0.9)
183H 3 (2.8)
185A 1 (0.9)
Pfdhps
431V 6 (5.6)
436A 11 (10.2)
437G 57 (52.8)
540E 71 (65.7)
581G 29 (26.9)
613S 1 (0.9)
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West and Central Africa as compared to East Africa and
Indian subcontinents (p=0.001).
Prevalence of pfdhps alleles and genotypes
Sequencing of the Pfdhps gene was successful for
108 (91.5%) isolates and overall 2.8% harbored wild
type alleles only, while the single mutant (S436A/
A437G/ K540E) allele was observed in 47.2%, double
mutant (S436A/K540E, A437G/K540E, K540E/A581G)
alleles in 39.8%, triple mutant (A437G/K540E/A581G)
allele in 6.5%, quadruple in 2.8% and 0.9% had
quintuple (431V/S436A/A437G/A581G/613S) mutant
alleles (Figure 2). No triple or quadruple mutation
was observed in the Indian subcontinent. A majority
of quadruple mutant genotypes was observed from
West and Central Africa origin. Furthermore, muta-
tions at 540E, 437G and 581G were frequent, occur-
ring at a prevalence of 65.7%, 52.8% and 26.9%,
respectively. Moreover, we found a single novel
point mutation (431V) in six (5.6%) isolates, of
these five were from Nigeria and one from Ghana
(Table 1). The mutation frequencies of the double
mutant alleles (540E/581G) were detected in 14.8%
isolates (437G/540E) in 19.4%, 1.8% for both (436A/
437G) and (431V/436A) and only 0.9% for both
(436A/540E) and (436A/581G). The triple mutant
alleles (437G, 540E, 581G), quadruple mutant alleles
(431V, 436A, 437G, 581G) and quintuple mutant
alleles (431V, 436A, 437G, 581G, 613S) were
detected in 6.5%, 2.8% and 0.9% of isolates, respec-
tively. Interestingly, significant quadruple mutants
were observed in West and Central Africa as
Figure 2. Mutation rates in P. falciparum genes (Pfdhfr,Pfdhps) that confer SP resistance from the isolates collected from East
Africa, West and Central Africa and Indian subcontinent.
Table 2. The frequency distribution of genotypes for Pfdhfr
and Pfdhps haplotypes among different nationalities.
Genotypes
Pfdhfr
East Africa
n = 67 (%)
Indian subconti-
nents
n = 20 (%)
West and Central
Africa
n = 21 (%)
ACICSILYT 3 (4.5) 1 (5) 1 (4.7)
ACNCNILYT 1 (1.5) 2 (10) 0
ACICNILYT 44 (65.7) 5 (25) 6 (28.6)
ACNRNILYT 2 (3) 6 (30) 0
ACIRNILYT 14 (20.9) 4 (20) 13 (62)
ACICNISYT 1 (1.5) 0 0
ACIRNILYA 1 (1.5) 0 0
ACIRNILHT 1 (1.5) 0 0
ACNCSILYT 0 1 (5) 0
ACNCNILHT 0 1 (5) 0
ACICNILHT 0 0 1 (4.7)
Pfdhps
Genotypes
East Africa
n = 69
(%)
Indian
subcontinents
n = 17 (%)
West and Central
Africa
n = 21 (%)
AAKAA 1 (1.4) 0 0
SGKAA 6 (8.7) 8 (47.1) 8 (38.1)
SAEAA 24 (34.8) 2 (11.8) 0
AAEAA 1 (1.4) 0 0
SGEAA 18 (26.1) 3 (17.6) 0
SGEGA 6 (8.7) 0 1 (4.8)
SAEGA 12 (17.4) 3 (17.6) 1 (4.8)
SAKGA 0 1 (5.9) 0
VAGKGA 0 0 3 (14.3)
VAGKGS 0 0 1 (4.8)
VAAKAA 0 0 2 (9.5)
AGKAA 0 0 2 (9.5)
AAKGA 0 0 1 (4.8)
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compared to East Africa and Indian subcontinents
(p=0.001).
Furthermore, the sulphadoxine (wild type) Pfdhps
genotype is SAKAA positioning 436, 437, 540, 581
and 613. In comparison to the wild type genotype
(SAKAA), seven genotypes (AAKAA, SGKAA, SAEAA,
AAEAA, SGEAA, SGEGA and SAEGA) were detected in
69 successfully sequenced samples from East Africa.
The prevalence of SAEAA genotype was higher
(34.8%) followed by SGEAA (26.1%), SAEGA (17.4%),
SGKAA and SGEGA (8.7% of each) genotype. In the
Indian subcontinents, of the 17 successfully
sequenced isolates, five genotypes (SGKAA, SAEAA,
SAKGA, SGEAA and SAEGA) were detected. Higher
prevalence of single mutant SGKAA (47.1%) was
noted followed by SAEGA and SGEAA (17.6% of
each) and 11.8% SAEAA genotype. In the case of
West and Central Africa, eight genotypes (SGKAA,
VAGKGA, VAGKGS, VAAKAA, AGKAA, AAKGA,
SGEGA and SAEGA) were detected in 21 successfully
sequenced isolates. The single mutant genotype
(SGKAA) was more prevalent and observed in 38.1%
of the isolates,14.3% had VAGKGA, 9.5% of each had
AGKAA and VAAKAA. Additionally, only single mutant
genotype (SGKAA) was observed in GCC isolate
(Table 2).
Polymorphisms of pfatpase6 and pfk13 genes
A total of 113 and 110 P. falciparum samples were
successfully genotyped for PfATPase6 and propeller
region of Pfk13 genes, respectively. All isolates carried
the wild type PfATPase6 gene. Furthermore, in Pfk13,
the frequency of mutations associated with ART resis-
tance reported in Southeast Asia was not observed.
However, only one non-synonymous mutation at
codon G453A was identified in isolate imported from
a sample of Kenyan origin.
The Pair-wise LD estimation to assess the selection
of P. falciparum resistant markers revealed a total of
37 possible pairs of SNPs with fine statistically signifi-
cance intragenic and intragenic associations were
found between different geographic regions from
a possible 154 points (Figure 3).
Discussion
Globally, emergence and spread of antimalarial drug
resistance of P. falciparum malaria is an important
deterrent in our fight against malaria. Recent reports
of tolerance/resistance to artemisinin derivatives and
spread of drug-resistant strains is a major concern, in
particular, the long-term effectiveness of artemisinin-
combination therapy (ACT) in Southeast Asia, Indian
subcontinents and Africa [23]. Antimalarial drug resis-
tance data is not available in Qatar and it has been
well established that human migration can interact
with natural features to establish drug resistance in
new areas. Thus, there is a need to monitor antimalar-
ial drug resistance in the migrant population and also
in native Qatari visiting endemic regions to stall the
potential spread of this deadly infection in Qatar.
Recently, we determined the current extent of chlor-
oquine resistance among imported P. falciparum
malaria and found a high prevalence of CQ resistance
patterns [19]. In the present study, the genetic poly-
morphism in the antimalarial drugs resistance genes
(Pfdhfr, Pfdhps, PfATPase6 and Pfk13) was investigated
among imported P. falciparum isolates in Qatar.
Resistance to SP was first reported from the Thai-
Cambodian border in the 1960s [24] and has spread
to several parts of Southeast Asia, South America and
Africa [25–27]. Resistance is likely to progress geogra-
phically and in intensity at a rising rate, becoming
fixed in the population if proper and timely measures
are not taken to interrupt it.
In this study, all the isolates were found mutated
and had at least one of 51I, 59R and 108N of Pfdhfr
alleles, while no mutation was seen at codon 164L.
Overall, the double mutant genotype (51I/108N) and
triple mutant genotype (51I, 59R, 108N) were found to
be more prevalent among the imported cases, which
are in agreement with well-established SP resistance
found in Africa and Southeast Asia [28,29]. Moreover,
the double mutant genotype (51I/108N) was predo-
minant from East African isolates than other areas
because the majority of the isolates were from
Sudan origin. The double mutation was prevalent in
Sudan in 2007 [30] and still maintains the double
mutant genotype with an emerging triple mutation
[31]. Triple mutants (51I, 59R, 108N), which associated
with high-
level pyrimethamine resistance [10,11], were almost
fixed in the African population [32,33]. High level of
triple mutant genotypes was also found in the present
study among isolates originates from Nigeria and
Cameroon, which is in agreement with other studies
[32,33]. Among the Indian sub-continent isolates, the
double (59R/108N and 51I/108N) mutants genotypes
were the most frequent genotypes followed by triple
(51I/59R/108N) mutant genotypes, which are in agree-
ment with previous reports from India [21,27,34–36].
Sulphadoxine resistance is mediated by a single
point mutation at codon 437G of the Pfdhps gene.
Higher levels of sulphadoxine resistance are associated
with double mutation at codons 437G/581G and triple
mutations at codons 436A/437G/613S [37]. In the pre-
sent study, 52.8% isolates had the key mutation at
codon 437G, whereas none of the isolates has key
mutations at both double (437G/581G) and triple muta-
tions [436A/437G/613S]. Approximately, 90% isolates
from East African origin had double mutation whereas
quadruple mutation arose in 19% isolates (Nigerian
origin) where triple and quadruple mutations are
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commonly prevalent [33]. Single point mutation at
codon 437G was higher in Indian subcontinents isolates
followed by West & Central Africa and East Africa. These
findings corroborate with earlier reports from India
[21,34,35]. Additionally, we found a novel mutation at
codon 431V in five isolates imported from Nigeria and
one isolate imported from Ghana, which corroborates
with previous findings of imported malaria infections in
the UK, which also originated from Nigeria [38] and also
pregnant women from Cameroon [39], suggesting that
this mutation is emerging especially in West Africa.
Recently, mutation at 431V in combination with 436A,
437G, 581G and 613S was found to be the most com-
mon in a Nigerian cohort [40].
The presence of key mutations in Pfdhfr and
Pfdhps genes along with the emergence of new
mutations and quadruple mutations at dhfr locus
and quadruple/quintuple mutations in dhps locus
are important findings which might be the cause
for multidrug resistance of antifolate drugs. The
emergence of these novel mutations might have
enhanced the level of antifolate resistance to
P. falciparum hence it should be taken into consid-
eration when using the combination of antifolate
drugs with artemisinin derivatives nationwide and
also where the double mutant genotype of Pfdhfr
(ACICNILYT) is common [21,41,42].
The artemisinin-
combination therapy (ACT) is recommended by the
WHO as the first-line treatment for P. falciparum infec-
tions in all endemic regions [1] and also in non-
endemic countries like Qatar [4]. In spite of these
efforts, there have been sporadic reports of an in-
vivo and an in-vitro artemisinin resistance during the
last few years [43–45]. However, the mechanism of
artemisinin resistance is still under investigation.
Subsequently, ACT resistance is considered a major
risk to public health in Southeast Asia and Sub-
Saharan Africa, where the burden is serious. The
mutations of Pfk13-propeller are well established in
Southeast Asia, whereas only limited polymorphisms
of Pfk13-propeller are detected in Africa [16,46].
Recently, in China, polymorphism in Pfk13 was
reported in returned migrant workers from Africa
[47]. Thus, there is now a clear need to acquire
a greater understanding of Plasmodium parasites’
genotypic resistance surveillance with k13-propeller
polymorphism. In the present study, k13 propeller
sequence analysis of P. falciparum parasites from dif-
ferent malaria-endemic areas in East Africa, Indian
Figure 3. Linkage disequilibrium (LD) between pairs of SNPs located in Pfdhfr, Pfdhps genes implicated in SP drug resistance in
imported P. falciparum cases in Qatar. The intra and inter-genic association between genes for the isolates collected from East
Africa, West and Central Africa and Indian subcontinent were determined using the LD plot. The strength of LDbetween the
SNPs was determined from the association of statistical significance by calculating the r2 values and represented by the
darkness of the boxes.
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sub-continent and West & Central Africa did not
detect the predicted artemisinin-resistant genotypes,
but we observed only one non-synonymous mutation
at codon G453A in a Kenyan isolate. Although anti-
malarial drug resistance originates from the greater
Mekong sub-
region and subsequently spread worldwide, still we
do not have any functional mutation from sub-
Saharan Africa [48–50]. No mutations in PfATPase6
were found in the current study, which is in agree-
ment with previous reports from India and Africa,
where PfATPase6 polymorphisms rarely reported [51–
55]. Another marker Pfmdr1 is also considered as qui-
nine, mefloquine, lumefantrine and ACT resistant mar-
kers [56] and recently we have reported only 28%
mutant or mixed genotype at N86 codon using the
same samples [19].
Although the molecular findings were not further
matched with treatment outcome and in-vitro drug
sensitivity of the falciparum isolates, which does not
allow us to make a correct evaluation about the level
of sensitivity of P. falciparum isolates, including the
possible role of the novel Pfdhps, Pfdhfr genotypes
because of the limitations of the present study. But
at the same time, many studies have proved that the
quadruple Pfdhfr/Pfdhps combined haplotype (59R +
108N/437G + 540E) are directly associated with either
adequate clinical and parasitological response, early
treatment failures or late parasitological failures to SP
[11,35,57]. Similarly, the reduced efficacy of artemisi-
nin associated with the presence of the functional
mutation in the K-13 gene [44,45].
In conclusion, the present study shows a high pre-
valence of resistance patterns of SP drugs to
P. falciparum in imported cases of malaria, which
might be helpful for the enrichment of molecular
surveillance of antimalarial resistance. In addition,
the emergence of new mutations in Pfdhfr and
Pfdhps genes requires further study to monitor the
changes in the frequency of mutation. In addition,
the current findings also raise a concern about the
potential effectiveness of the current first line of drug,
i.e. ACT. Hence, the baseline data on antimalarial drug
resistance will help policymakers in updating national
antimalarial guidelines for the treatment of imported
malaria cases in Qatar.
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